Clinical trial
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
NCT00473746 · Janssen Research & Development, LLC, Industry · Completed
Key facts
| NCT number | NCT00473746 |
|---|---|
| Title | Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer |
| Official title | Phase I/II Open Label Dose Escalation Study of the 17α-Hydroxylase/ C17,20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer |
| Lead sponsor | Janssen Research & Development, LLC, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Neoplasms |
| Intervention type | Drug |
| Interventions | Abiraterone acetate, prednisone/prednisolone or dexamethasone |
| Enrollment | 66 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | May 15, 2007 |
| Last update posted | Apr 29, 2014 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: